BioSpace News Archive

The exact implications of the paxalisib disappointment are still unclear, though it is highly likely that the candidate will be dropped from the GBM AGILE umbrella trial.

According to two recent studies, 10 to 30% of people with COVID-19 reported at least one persistent symptom up to six months after infection, which qualifies as Long COVID.

The annual Alzheimer’s Association International Conference (AAIC) is running from July 31-August 4 at the San Diego Convention Center and online. Here are some of the highlights presented so far.

The FDA has placed a clinical hold on Beam Therapeutics’ leukemia/lymphoma therapy and has lifted the hold on Celyad’s CAR-T candidate for colorectal cancer.

AbbVie and Sosei add neurological targets in new deal, TransCode and MD Anderson partner on RNA cancer therapies and Xenetic and VolitionRx unite to develop NETs-targeted therapies against cancer.

Whistleblowers Erika Cheung and Tyler Shultz discussed their experiences at Theranos during the recent 2022 AACC Annual Scientific Meeting & Clinical Lab Expo.

Gilead’s total revenue for Q2 increased 1% to $6.3 billion compared to Q2 in 2021. Overall, the company exceeded both its own expectations and the predictions of market analysts for the second quarter.

IDRx aims to create highly selective and aligned drug combinations to stop key tumor escape mechanisms that will support prolonged and durable responses to therapy.

Factors that led to Allarity’s decision include the viability of existing opportunities, funding availability, development timelines and costs and commercial and regulatory risks.

According to Transparency Market Research’s latest report on the global 3D printing in medical application market for the historical period 2017–2019 and forecast period 2021–2028, increase in demand for customized 3D printing in medical applications is projected to drive the global 3D printing in medical application market during the forecast period